Generation of functional insulin-producing cells in the gut by Foxo1 ablation. Talchai C, Xuan S, Kitamura T, DePinho RA, Accili D (2012) Nat Genet 44: 406-12, S1 Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR (2014) JAMA 311: 2288-96 Role of sulfonylurea receptor type 1 subunits of ATP-sensitive potassium channels in myocardial ischemia/reperfusion injury. Elrod JW, Harrell M, Flagg TP, Gundewar S, Magnuson MA, Nichols CG, Coetzee WA, Lefer DJ (2008) Circulation 117: 1405-13 Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR (2012) Ann Intern Med 157: 601-10 β-Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion. Barella LF, Rossi M, Zhu L, Cui Y, Mei FC, Cheng X, Chen W, Gurevich VV, Wess J (2019) J Clin Invest 129: 3732-3737 Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. Hande KR, Kuttesch J, Hamilton M, Satterlee W, Jackson L, Grindey G, Hainsworth JD (1990) Cancer Res 50: 3910-4 Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Hainsworth JD, Hande KR, Satterlee WG, Kuttesch J, Johnson DH, Grindey G, Jackson LE, Greco FA (1989) Cancer Res 49: 5217-20 Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Ikizler TA, Griffin MR (2012) Kidney Int 81: 698-706 Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpiling. Greevy RA, Huizinga MM, Roumie CL, Grijalva CG, Murff H, Liu X, Griffin MR (2011) Clin Pharmacol Ther 90: 813-9 Linkage studies in NIDDM with markers near the sulphonylurea receptor gene. Stirling B, Cox NJ, Bell GI, Hanis CL, Spielman RS, Concannon P (1995) Diabetologia 38: 1479-81 Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. Roumie CL, Min JY, Greevy RA, Grijalva CG, Hung AM, Liu X, Elasy T, Griffin MR (2016) CMAJ 188: E104-E112 Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B (2013) Diabetes Obes Metab 15: 42-54 Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, Ikizler TA, Griffin MR (2016) Clin J Am Soc Nephrol 11: 2177-2185 Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. Miura A, Yamagata K, Kakei M, Hatakeyama H, Takahashi N, Fukui K, Nammo T, Yoneda K, Inoue Y, Sladek FM, Magnuson MA, Kasai H, Miyagawa J, Gonzalez FJ, Shimomura I (2006) J Biol Chem 281: 5246-57 Individual sulfonylureas and serious hypoglycemia in older people. Shorr RI, Ray WA, Daugherty JR, Griffin MR (1996) J Am Geriatr Soc 44: 751-5 Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes. Min JY, Griffin MR, Hung AM, Grijalva CG, Greevy RA, Liu X, Elasy T, Roumie CL (2016) J Gen Intern Med 31: 638-46 Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Murff HJ, Roumie CL, Greevy RA, Hackstadt AJ, McGowan LED, Hung AM, Grijalva CG, Griffin MR (2018) Cancer Causes Control 29: 823-832 Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals. Joy NG, Tate DB, Davis SN (2015) Metabolism 64: 729-37 Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year. Roumie CL, Liu X, Choma NN, Greevy RA, Hung AM, Grijalva CG, Griffin MR (2012) Pharmacoepidemiol Drug Saf 21: 515-23 Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. Huizinga MM, Roumie CL, Greevy RA, Liu X, Murff HJ, Hung AM, Grijalva CG, Griffin MR (2010) Pharmacoepidemiol Drug Saf 19: 1108-12 Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Griffin MR (2013) Pharmacoepidemiol Drug Saf 22: 623-31 The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. Roumie CL, Huizinga MM, Liu X, Greevy RA, Grijalva CG, Murff HJ, Hung AM, Griffin MR (2011) Pharmacoepidemiol Drug Saf 20: 36-44 Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Griffin MR (2016) BMC Endocr Disord 16: 32 The use of sequential pattern mining to predict next prescribed medications. Wright AP, Wright AT, McCoy AB, Sittig DF (2015) J Biomed Inform 53: 73-80
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.